Profile data is unavailable for this security.
About the company
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).
- Revenue in USD (TTM)73.62m
- Net income in USD-138.24m
- Incorporated1995
- Employees145.00
- LocationEnanta Pharmaceuticals Inc500 Arsenal StreetWATERTOWN 02472United StatesUSA
- Phone+1 (617) 607-0800
- Fax+1 (617) 607-0530
- Websitehttps://www.enanta.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc | 21.25m | -16.05m | 249.59m | 36.00 | -- | -- | -- | 11.74 | -0.6042 | -0.6042 | 0.7994 | -0.43 | 0.79 | 0.9217 | 4.10 | -- | -59.64 | -73.43 | -77.06 | -84.32 | 94.08 | -- | -75.50 | -383.28 | 3.27 | -3.90 | 1.63 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Pyxis Oncology Inc | 0.00 | -73.79m | 249.97m | 50.00 | -- | 1.53 | -- | -- | -1.87 | -1.87 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -38.32 | -- | -45.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.87 | -- | -- | -- |
| TriSalus Life Sciences Inc | 18.51m | -63.28m | 250.19m | 112.00 | -- | -- | -- | 13.52 | -1.84 | -1.84 | 0.5991 | -0.982 | 0.7758 | 1.30 | 7.24 | 165,267.90 | -247.43 | -- | -17,440.77 | -- | 85.93 | -- | -318.95 | -- | 1.25 | -13.69 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Invivyd Inc | 0.00 | -198.64m | 256.33m | 94.00 | -- | 1.33 | -- | -- | -1.81 | -1.81 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -64.88 | -- | -73.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Sutro Biopharma Inc | 153.73m | -106.79m | 258.17m | 302.00 | -- | 1.39 | -- | 1.68 | -1.79 | -1.79 | 2.56 | 2.45 | 0.3503 | -- | 7.12 | 509,043.00 | -24.34 | -25.48 | -29.77 | -29.75 | -- | -- | -69.47 | -113.71 | -- | -- | 0.0264 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Boundless Bio Inc | 0.00 | -49.43m | 258.87m | 72.00 | -- | -- | -- | -- | -2.22 | -2.22 | 0.00 | 5.42 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Chromadex Corp | 83.57m | -4.94m | 259.06m | 106.00 | -- | 9.06 | -- | 3.10 | -0.0659 | -0.0659 | 1.11 | 0.3795 | 1.53 | 2.25 | 21.38 | 788,396.30 | -9.06 | -42.11 | -14.00 | -65.14 | 60.76 | 59.68 | -5.91 | -30.64 | 1.70 | -- | 0.0008 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Xeris Biopharma Holdings Inc | 163.91m | -62.26m | 259.44m | 377.00 | -- | -- | -- | 1.58 | -0.4525 | -0.4525 | 1.19 | -0.0491 | 0.4914 | 0.9012 | 4.68 | 434,785.20 | -18.66 | -43.60 | -24.99 | -56.57 | 82.52 | 78.23 | -37.98 | -143.08 | 1.23 | -2.01 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Acrivon Therapeutics Inc | 0.00 | -60.39m | 261.18m | 58.00 | -- | 1.57 | -- | -- | -2.73 | -2.73 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -37.80 | -- | -40.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| Enanta Pharmaceuticals Inc | 73.62m | -138.24m | 261.70m | 145.00 | -- | 1.36 | -- | 3.55 | -6.56 | -6.56 | 3.50 | 9.07 | 0.1897 | -- | 4.79 | 507,737.90 | -35.63 | -14.56 | -40.03 | -15.62 | -- | -- | -187.77 | -54.96 | -- | -- | 0.0074 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Vanda Pharmaceuticals Inc. | 192.64m | 2.51m | 265.82m | 203.00 | 105.36 | 0.4878 | 48.17 | 1.38 | 0.0439 | 0.0439 | 3.35 | 9.47 | 0.3004 | 11.60 | 5.69 | 948,965.50 | 0.3912 | 6.61 | 0.4547 | 7.62 | 92.32 | 90.55 | 1.30 | 15.18 | 4.92 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Monte Rosa Therapeutics Inc | 0.00 | -135.35m | 267.32m | 133.00 | -- | 1.49 | -- | -- | -2.64 | -2.64 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -41.90 | -- | -47.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 832.01k | -135.12m | 267.73m | 122.00 | -- | 2.05 | -- | 321.79 | -6.12 | -6.12 | 0.0375 | 5.15 | 0.0032 | -- | 0.9778 | 6,819.75 | -52.02 | -59.52 | -71.11 | -71.29 | -- | -- | -16,239.87 | -4,097.36 | -- | -- | 0.125 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| ESSA Pharma Inc | 0.00 | -25.80m | 268.97m | 50.00 | -- | 1.91 | -- | -- | -0.5851 | -0.5851 | 0.00 | 3.19 | 0.00 | -- | -- | 0.00 | -16.68 | -23.01 | -17.03 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Inozyme Pharma Inc | 0.00 | -71.17m | 274.27m | 59.00 | -- | 1.95 | -- | -- | -1.39 | -1.39 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -41.86 | -45.00 | -45.82 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2417 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Avenue Therapeutics Inc | 0.00 | -10.38m | 274.42m | 3.00 | -- | 1.34 | -- | -- | -133.23 | -133.23 | 0.00 | 4.64 | 0.00 | -- | -- | 0.00 | -241.24 | -186.91 | -382.29 | -287.70 | -- | -- | -- | -- | -- | -70.24 | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Enanta Pharmaceuticals Inc's reporting currency: US Dollar USD
61.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2023 | 2.06m | 9.76% |
| Farallon Capital Management LLCas of 31 Dec 2023 | 2.03m | 9.57% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.77m | 8.39% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.58m | 7.49% |
| Millennium Management LLCas of 05 Jan 2024 | 1.31m | 6.22% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.05m | 4.98% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 935.49k | 4.42% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 842.94k | 3.98% |
| Krensavage Asset Management LLCas of 31 Dec 2023 | 742.82k | 3.51% |
| D. E. Shaw & Co. LPas of 31 Dec 2023 | 638.17k | 3.02% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
